ADARx Pharmaceuticals, Inc. ADRX
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -13.64% | -14.93% | 0.00% | -9.00% | -16.35% |
| Total Depreciation and Amortization | 2.08% | 21.31% | 0.00% | -5.19% | 21.79% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 127.96% | -42.17% | 0.00% | 186.38% | -45.61% |
| Change in Net Operating Assets | -164.46% | -15.22% | 0.00% | -100.36% | 20,091.39% |
| Cash from Operations | -19.89% | -17.97% | 0.00% | -106.13% | 2,567.09% |
| Capital Expenditure | -376.62% | 89.35% | 0.00% | 27.12% | -99.60% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 10.46% | -1.65% | 0.00% | 107.77% | -1,915.73% |
| Cash from Investing | 9.05% | 1.57% | 0.00% | 107.47% | -1,987.57% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 200.00% | -71.43% | 0.00% | -91.57% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 200.00% | -71.43% | 0.00% | -91.57% | -- |
| Foreign Exchange rate Adjustments | -22.95% | 1,009.09% | 0.00% | -69.44% | 400.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -102.11% | -709.86% | 0.00% | -99.13% | 3,992.61% |